Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Lenalidomide + dexamethasone is a combination therapy primarily used to treat multiple myeloma, a cancer of plasma cells. Lenalidomide is an immunomodulatory agent and thalidomide derivative that works by altering cytokine production, regulating T cell co-stimulation, enhancing natural killer (NK) cell-mediated cytotoxicity, and directly inhibiting the cullin ring E3 ubiquitin ligase complex via binding to cereblon. This leads to the degradation of key transcription factors (IKZF1 and IKZF3), which are essential for malignant plasma cell survival[4][6]. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties; in this combination it enhances the anti-myeloma effect of lenalidomide[5]. The primary indication for this combination is multiple myeloma, both as initial therapy and as maintenance following autologous stem cell transplant[1][2][8].
- Brand names
- Revlimid + dexamethasone
- Other names
- none
02
Targets
GR (Glucocorticoid receptor)CRBN (Cereblon)
Beyond the preview
Go deeper on lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + dexamethasone.